Biotech · Private company · Phoenix, AZ, US
Faknostics, LLC
Track this companyFree. Adds Faknostics, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards6
- Novel Paxillin-FAK Inhibitors for the Treatment of Liver FibrosisFiscal year 2026 · $669.5KNIH RePORTER 5R42DK141379-03 · fetched Nov 12, 2026
- Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosisFiscal year 2026 · $662.6KNIH RePORTER 5R42HL162392-04 · fetched Nov 12, 2026
- Novel Paxillin-FAK Inhibitors for the Treatment of Liver FibrosisFiscal year 2025 · $663.8KNIH RePORTER 4R42DK141379-02 · fetched Nov 12, 2026
- Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosisFiscal year 2025 · $663.3KNIH RePORTER 5R42HL162392-03 · fetched Nov 12, 2026
- Novel Paxillin-FAK Inhibitors for the Treatment of Liver FibrosisFiscal year 2024 · $326KNIH RePORTER 1R42DK141379-01 · fetched Nov 12, 2026
- Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosisFiscal year 2024 · $673.8KNIH RePORTER 2R42HL162392-02 · fetched Nov 12, 2026